$922 Million is the total value of VR Adviser, LLC's 28 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TIL | New | INSTIL BIO INC | $172,176,000 | – | 6,865,076 | +100.0% | 18.68% | – |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $93,759,000 | +641.3% | 3,720,582 | +90.3% | 10.17% | +446.9% |
| CGEM | New | CULLINAN MANAGEMENT INC | $49,010,000 | – | 1,176,145 | +100.0% | 5.32% | – |
| Buy | MARINUS PHARMACEUTICALS INC | $40,895,000 | +29.5% | 2,641,809 | +2.0% | 4.44% | -4.5% | |
| VTGN | Buy | VISTAGEN THERAPEUTICS INC | $34,725,000 | +91.2% | 16,302,596 | +74.2% | 3.77% | +41.1% |
| RLMD | Buy | RELMADA THERAPEUTICS INC | $30,041,000 | +40.1% | 853,206 | +27.6% | 3.26% | +3.4% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC | $25,557,000 | +82.3% | 1,240,610 | +55.1% | 2.77% | +34.5% |
| PHVS | New | PHARVARIS BV | $25,335,000 | – | 902,882 | +100.0% | 2.75% | – |
| EPIX | New | ESSA PHARMA INC | $18,178,000 | – | 625,754 | +100.0% | 1.97% | – |
| ACET | New | ADICET BIO INC | $13,080,000 | – | 1,000,000 | +100.0% | 1.42% | – |
| New | APTOSE BIOSCIENCES INC | $9,592,000 | – | 1,605,400 | +100.0% | 1.04% | – | |
| ALGS | Buy | ALIGOS THERAPEUTICS INC | $9,286,000 | -17.1% | 408,377 | +0.9% | 1.01% | -38.8% |
| EYPT | New | EYEPOINT PHARMACEUTICALS INC | $7,112,000 | – | 700,000 | +100.0% | 0.77% | – |
| TSHA | Buy | TAYSHA GENE THERAPIES INC | $2,449,000 | -14.5% | 120,649 | +11.7% | 0.27% | -36.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 12 | Q3 2023 | 12.7% |
| VIRIDIAN THERAPEUTICS INC | 12 | Q3 2023 | 13.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.3% |
| RELMADA THERAPEUTICS INC | 11 | Q3 2022 | 9.9% |
| GH RESEARCH PLC | 10 | Q3 2023 | 6.7% |
| ALTIMMUNE INC | 9 | Q3 2022 | 11.6% |
| MARINUS PHARMACEUTICALS INC | 9 | Q4 2022 | 5.7% |
| CELLDEX THERAPEUTICS INC | 9 | Q3 2022 | 7.6% |
| AFFIMED N V | 8 | Q3 2023 | 1.1% |
| INSTIL BIO INC | 7 | Q3 2022 | 18.7% |
View VR Adviser, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View VR Adviser, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.